Chemistry:Raseglurant
From HandWiki
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C15H13FN2 |
| Molar mass | 240.281 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Raseglurant (INN) (code name ADX-10059) is a negative allosteric modulator of the mGlu5 receptor and derivative of MPEP which was under development by Addex Therapeutics for the treatment of migraine, gastroesophageal reflux disease, and dental anxiety.[1][2][3] It reached phase II clinical trials for all of the aforementioned indications before being discontinued due to the observation of possible predictive signs of hepatotoxicity in patients with long-term use.[3][4][5]
See also
References
- ↑ "mGluR2 activators and mGluR5 blockers advancing in the clinic for major CNS disorders.". Annual Reports in Medicinal Chemistry. 47. Academic Press. January 2012. pp. 71–88. ISBN 978-0-12-397214-9. https://books.google.com/books?id=y7GH165YoOsC&pg=PA80.
- ↑ "Don't Dodge the Dentist – Tips for Dealing with Dental Anxiety" (in en-US). http://www.comfortfirstdentalsterling.com/dont-dodge-the-dentist-tips-for-dealing-with-dental-anxiety/.
- ↑ 3.0 3.1 Behavioral Neurobiology of Anxiety and Its Treatment. Springer Science & Business Media. 30 July 2010. pp. 397–. ISBN 978-3-642-02912-7. https://books.google.com/books?id=vlCV3D7J0bEC&pg=PA397.
- ↑ Neurodegenerative Diseases. Springer Science & Business Media. 18 November 2010. pp. 120–. ISBN 978-3-642-16758-4. https://books.google.com/books?id=m3e8VHphbwcC&pg=PA120.
- ↑ Benign and Neoplastic Conditions of the Esophagus, An Issue of Gastroenterology Clinics. Elsevier Health Sciences. 25 March 2013. pp. 119–. ISBN 978-1-4557-7175-2. https://books.google.com/books?id=F5f6rmvFzi8C&pg=PT119.
External links
 |  |
